Portfolio company
Neumann Diagnostics
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops molecular and epigenetic diagnostic tests for cervical cancer screening and human papillomavirus detection for healthcare laboratories and clinical providers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Teal Health
This company develops an at-home self-collection device for cervical cancer screening for women.
Teal Health
This company develops at-home cervical cancer screening devices and telehealth services for women, health systems, and employers.
Pink Dx
The company develops non-invasive molecular diagnostic tests for the early detection of gynecological cancers for women and their healthcare providers.
Epigenomics
This molecular diagnostics company develops blood-based liquid biopsy tests for the early detection and screening of cancer for healthcare providers and clinical laboratories.
Sakura MedTech
This company develops a tampon-shaped imaging device for cervical cancer screening to replace the traditional speculum for clinicians and their patients.
Naveris
This molecular diagnostics company develops and commercialises liquid biopsy tests for the early detection and clinical management of viral-associated cancers for healthcare providers.
Cispoly
This company develops methylation detection kits for the early diagnosis of gynaecological cancers for healthcare providers and public health initiatives.
Nanopath
This company develops point-of-care molecular diagnostic tests and hardware for pelvic and gynecologic infections to provide rapid results for healthcare providers and their patients.
